CMMB Chemomab Therapeutics Ltd. ADRs

Chemomab is a clinical-stage biopharmaceutical company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. Chemomab is currently testing CM-101 in three phase 2 studies focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc)

$46.12  -8.88 (-16.15%)
As of 04/09/2021 15:59:21 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Israel
Country of incorporation:  
IPO date:  02/12/2019
Outstanding shares:  10,697,975
Average volume:  300,572
Market cap:   $491,037,053
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   137.28
PS ratio:   0.00
Return on equity:   -324.55%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy